Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs iShares Russell 2000 ETF (IWM) Price & Performance

Bristol-Myers Squibb CoTrade
iShares Russell 2000 ETFTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs iShares Russell 2000 ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while iShares Russell 2000 ETF trades at $302.92. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while iShares Russell 2000 ETF pays none. Which is the better fit depends on your goals.

BMYIWM
Market Cap
$129.94B
Sector
Health
52-Week High
$65.89$301.69
52-Week Low
$42.60$225.45
Enterprise Value
$163.92B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

iShares Russell 2000 ETF

IWM, the iShares Russell 2000 ETF tracking US small-cap stocks, trades at $302.33 with a 0.78% daily gain. Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions. The ETF benefits from institutional preference due to its liquidity and options ecosystem, with recent news highlighting small-cap outperformance versus large caps in 2026.

Outlook remains positive as small caps lead market gains, but risks include higher volatility and competition from lower-cost alternatives. Institutional inflows and broadening market participation support further upside, though valuation concerns and economic sensitivity warrant monitoring.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About iShares Russell 2000 ETF

The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on IWM